Tech Company Financing Transactions
Ukko Funding Round
On 1/28/2021, Ukko raised $40 million in Series B financing from Leaps by Bayer, Continental Grain Company and Fall Line Capital.
Transaction Overview
Company Name
Announced On
1/28/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Leaps by Bayer (Lead Investor) (Juergen Eckhardt)
private investors (Marc Benioff)
Proceeds Purpose
The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1845 El Camino Real
Palo Alto, CA 94306
USA
Palo Alto, CA 94306
USA
Phone
Undisclosed
Website
Email Address
Overview
Ukko is improving the lives of millions that suffer from food allergies and disorders. We are using cutting edge technologies in immunology, computational biology, and plant science to develop a new approach. We have offices in Tel Aviv, Israel and Palo Alto, California.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Yanay Ofran
Chief Executive Officer
Anat Binur
Browse more venture capital transactions:
Prev: 1/28/2021: Doorvest venture capital transaction
Next: 1/28/2021: RxREVU venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs